Ticker

Its lead T-Cell Engager HCW11-018b is shown to penetrate into the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer activities

MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, today reported financial results and recent business highlights for its three months ended December 31, 2025.

HCW Biologics (NASDAQ: HCWB - Get Free Report) is expected to be announcing its results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.84) per share and revenue of $7.0120 million for the quarter. HCW Biologics Stock Down 17.9% Shares of NASDAQ: HCWB opened at $0.43 on Wednesday. HCW

Upfront cash fee with total value of $7.0 million, comprised of a $3.5 million cash payment and $3.5 million in-kind payment in the form of a transferable equity interest in licensee

Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer